A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

By D. Tashkin, Bartolome Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, M. Decramer. New England Journal of Medicine, 2008

2,058 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, neutral): “В крупном длительном клиническом исследовании до бавление тиотропия к стандартной схеме лечения не оказывало влияния на снижение легочной функции и по казатели сердечно сосудистого риска у пациентов с ХОБЛ [214].”
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. (2007, methodology): “COPD should be treated as usual, as there is no evidence that COPD should be treated differently in the presence of IHD (75, 79, 177).”
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. (2017, background): “Bronchodilators have been previously described as potentially pro-arrhythmic agents;(314,315) however, evidence suggests an overall acceptable safety profile for long-acting beta2-agonists, 316 anticholinergic drugs (and inhaled corticosteroids).(103,115,253,317-322) Page 42 of 74 AJRCCM Articles in”